Expected in the first half of 2028, the planned separation would create a stand-alone retail pharmacy company with nearly 30,000 pharmacists.
|Articles|February 10, 2022
Daily Medication Pearl: Diroximel Fumarate (Vumerity)
Author(s)Saro Arakelians, PharmD
Diroximel fumarate (Vumerity) is indicated for the treatment of relapsing forms of multiple sclerosis.
Advertisement
Medication Pearl of the Day: Diroximel fumarate (Vumerity)
Indication: Diroximel fumarate (Vumerity)is indicated for the treatment of relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Insight:
- Dosing: Starting dose 231 mg twice a day, orally, for 7 days. Maintenance dose after 7 days 462 mg administered as two 231 mg capsules twice a day, orally.
- Dosage forms: Delayed-release capsules 231 mg.
- Adverse events: Most common adverse reactions for dimethyl fumarate were flushing, abdominal pain, diarrhea, and nausea.
- Mechanism of action: MMF, the active metabolite of diroximel fumarate, has been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathways in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. MMF has been identified as a nicotinic acid receptor agonist in vitro.
- Manufacturer: Biogen
Sources:
Advertisement
Related to this article
Doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd (Voceryq) targets HPV-6 and HPV-11 to reduce the surgical burden for adults with recurrent respiratory papillomatosis, a rare airway disease.
Cody Parsons, APh, PharmD, BCCCP, says protected pharmacist access lets patients with heart failure be seen more often than typical clinic visits allow.
The evidence for GLP-1 receptor agonists keeps growing, while access for low-income patients keeps narrowing.
Specialty pharmacists can help patients with cancer weigh the benefits and risks of GLP-1 receptor agonists as use expands and new evidence emerges.
If gene therapies are expected to deliver decades of benefit, long-term evidence collection must be coordinated, useful to patients, and financially sustainable.
As kratom questions increase, many pharmacists and other health care professionals may remain unfamiliar it and the potential risks.
Pharmacists can work alongside dermatologists, nurses, and other health care professionals to help answer skin care–related questions and help patients understand trial outcomes.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Understanding Kratom: Pharmacology, Safety, and Regulation
2
GLP-1s and Obesity Care: Cardiorenal Outcomes, Prescribing Considerations, and Access Barriers
3
GLP-1 Receptor Agonists and Cancer: Considerations for Specialty Pharmacists
4
How Stanford Pharmacists Help Close Heart Failure Therapy Gaps
5